SynthesisJournal of the American Heart Association2018
Genome-Wide Association Approach Identified Novel Genetic Predictors of Heart Rate Response to β-Blockers.
Synthesis in Journal of the American Heart Association, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00246519 (Pharmacogenomic Evaluation of Antihypertensive Responses), which is not on this map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR)
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.
- Redefining β-blocker response in heart failure patients with sinus rhythm and atrial fibrillation: a machine learning cluster analysis.Lancet (London, England) · 2021Pooled it
- Trans-ethnic meta-analysis identifies new loci associated with longitudinal blood pressure traits.Scientific reports · 2021Pooled it
- Pharmacogenetic and microRNA mechanisms of beta blocker use on bone.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2025Trial
- βJournal of clinical pharmacology · 2019Trial
- Metatranscriptomic analysis of upper and lower respiratory tract microbiomes in patients with tuberculosis and community-acquired pneumonia.BMC infectious diseases · 2026Article
- Impact of Genetic Variation in Adrenergic Receptors on β-Blocker Effectiveness and Safety in Cardiovascular Disease Management: A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Article
- Sorting nexins: role in the regulation of blood pressure.The FEBS journal · 2023Review
- Pharmacogenomic Effects of β-Blocker Use on Femoral Neck Bone Mineral Density.Journal of the Endocrine Society · 2021Article
- Integrative genomic analysis in African American children with asthma finds three novel loci associated with lung function.Genetic epidemiology · 2021Article
- Paroxetine Attenuates Cardiac Hypertrophy Via Blocking GRK2 and ADRB1 Interaction in Hypertension.Journal of the American Heart Association · 2021Article
- Article
- Polygenic Score for β-Blocker Survival Benefit in European Ancestry Patients With Reduced Ejection Fraction Heart Failure.Circulation. Heart failure · 2020Article
- Molecular Variants in Human Trace Amine-Associated Receptors and Their Implications in Mental and Metabolic Disorders.Cellular and molecular neurobiology · 2020Review
- The emerging role of sorting nexins in cardiovascular diseases.Clinical science (London, England : 1979) · 2019Review
- An Ancestry Informative Marker Set Which Recapitulates the Known Fine Structure of Populations in South Asia.Genome biology and evolution · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 1 country.
Funding
Abstract
backgroundFor many indications, the negative chronotropic effect of β-blockers is important to their efficacy, yet the heart rate (HR) response to β-blockers varies. Herein, we sought to use a genome-wide association approach to identify novel single nucleotide polymorphisms (SNPs) associated with HR response to β-blockers. METHODS AND
resultsWe first performed 4 genome-wide association analyses for HR response to atenolol (a β1-adrenergic receptor blocker) as: (1) monotherapy or (2) add-on therapy, in 426 whites and 273 blacks separately from the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) study. A meta-analysis was then performed between the genome-wide association analysis performed in PEAR atenolol monotherapy and add-on therapy, in each race separately, using the inverse variance method assuming fixed effects. From this analysis, SNPs associated with HR response to atenolol at a
conclusionsThis study highlights CLINICAL
trial registrationURL: http://www.clinicaltrials.gov. Unique identifier: NCT00246519.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.